To the full analysis
Sartorius Stedim Biotech stock: growth
DIM.PASartorius Stedim Biotech reported $3.29B in revenue for fiscal 2025, up 6.7% on the prior year, up 9.2% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
9.6%
per year from 2006 to 2025, per share 9.9%
Earnings (Annual rate)
12.4%
per year from 2006 to 2025, per share 12.7%
Free cash flow (Annual rate)
10.9%
per year from 2006 to 2025, per share 11.2%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 9.2% | 12.9% | 9.6% |
| Revenue per share | 8.0% | 12.3% | 9.9% |
| Earnings | −4.6% | 8.5% | 12.4% |
| Earnings per share | −5.6% | 7.9% | 12.7% |
| Free cash flow | −10.8% | 4.9% | 10.9% |
| Free cash flow per share | −11.8% | 4.4% | 11.2% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $577.38M | $32.16M | $22.72M |
| 2007 | $297.9M | $5.25M | $13.67M |
| 2008 | $407.78M | $14.52M | $29.91M |
| 2009 | $444.6M | $32.24M | $84.01M |
| 2010 | $479.75M | $42.67M | $62.14M |
| 2011 | $528.9M | $47.86M | $24.42M |
| 2012 | $602.77M | $62.89M | $11.24M |
| 2013 | $651.98M | $73.44M | $67.41M |
| 2014 | $757.41M | $80.31M | $71.19M |
| 2015 | $979.93M | $130.75M | $99.51M |
| 2016 | $1.17B | $170.29M | $85.26M |
| 2017 | $1.2B | $178.5M | $53.04M |
| 2018 | $1.34B | $230.54M | $56.23M |
| 2019 | $1.6B | $259.93M | $192.98M |
| 2020 | $2.12B | $372.25M | $285.54M |
| 2021 | $3.2B | $459.2M | $412.2M |
| 2022 | $3.87B | $970.81M | $201.34M |
| 2023 | $3.08B | $343.18M | $172.97M |
| 2024 | $3.08B | $194.03M | $526.68M |
| 2025 | $3.29B | $294.31M | $161.12M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 7 Aug 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.